Technical Analysis for AQST - Aquestive Therapeutics, Inc.

Grade Last Price % Change Price Change
grade C 5.27 -21.34% -1.43
AQST closed down 21.34 percent on Friday, December 13, 2019, on 9.8 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It was able to find support at its 50 day moving average. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Very Strong Up Flat Down
See historical AQST trend table...

Date Alert Name Type % Chg
New Downtrend Bearish 0.00%
50 DMA Support Bullish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Volume Surge Other 0.00%
Calm After Storm Range Contraction 0.00%
NR7 Range Contraction 0.00%
Doji - Bullish? Reversal 0.00%
Stochastic Reached Oversold Weakness 0.00%
Wide Bands Range Expansion 0.00%
Gapped Down Weakness 0.00%
Older signals for AQST ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on the development of treatments for diseases related to the central nervous system (CNS). Its CNS programs consist of a pipeline of products that include Libervant, Sympazan, and AQST-117. Libervant is a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures. Sympazan is an oral soluble film formulation of clobazam for the treatment of seizures associated with a rare, intractable form of epilepsy known as Lennox-Gastaut Syndrome. AQST-117 is an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The Company’s complex molecule programs consist of AQST-108, and AQST-305, for the treatment of anaphylaxis and neuroendocrine tumors respectively. The Company also has a pipeline of products under partner programs, which includes Suboxone and APL-130277 for the treatment of opioid dependence, and Parkinson’s disease.
Pharmaceutical Diseases Drugs Psychoactive Drugs Amyotrophic Lateral Sclerosis Epilepsy Chloroarenes Opioids Lactams Gabaa Receptor Positive Allosteric Modulators Parkinson’s Disease Neuroendocrine Tumors Riluzole

Is AQST a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 10.0
52 Week Low 2.95
Average Volume 775,974
200-Day Moving Average 4.86
50-Day Moving Average 5.25
20-Day Moving Average 7.13
10-Day Moving Average 7.75
Average True Range 0.86
ADX 50.45
+DI 22.04
-DI 26.69
Chandelier Exit (Long, 3 ATRs ) 7.42
Chandelier Exit (Short, 3 ATRs ) 7.68
Upper Bollinger Band 9.39
Lower Bollinger Band 4.87
Percent B (%b) 0.09
BandWidth 63.41
MACD Line 0.48
MACD Signal Line 0.81
MACD Histogram -0.3278
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.01
Resistance 3 (R3) 6.03 5.81 5.88
Resistance 2 (R2) 5.81 5.62 5.80 5.84
Resistance 1 (R1) 5.54 5.51 5.52 5.52 5.80
Pivot Point 5.32 5.32 5.31 5.31 5.32
Support 1 (S1) 5.05 5.13 5.03 5.03 4.74
Support 2 (S2) 4.83 5.02 4.82 4.70
Support 3 (S3) 4.56 4.83 4.66
Support 4 (S4) 4.54